BQR-695


CAS No. : 1513879-21-4

BQR-695,1513879-21-4
Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:I013052
Molecular Formula:C₁₉H₂₀N₄O₃
Molecular Weight:352.39
Target:PI4K
Price:Get quote
Inventory Status:In stock!
We would like to match the lowest price on market if possible.

Your information is safe with us.

refresh
Cat No:I013052
Cas No:1513879-21-4
Product-Name:BQR-695
IUPAC Name:2-[[7-(3,4-dimethoxyphenyl)quinoxalin-2-yl]amino]-N-methylacetamide
InChI:InChI=1S/C19H20N4O3/c1-20-19(24)11-22-18-10-21-14-6-4-12(8-15(14)23-18)13-5-7-16(25-2)17(9-13)26-3/h4-10H,11H2,1-3H3,(H,20,24)(H,22,23)
InChIKey:LYPCULYCGFOIDA-UHFFFAOYSA-N
SMILES:CNC(=O)CNC1=CN=C2C=CC(=CC2=N1)C3=CC(=C(C=C3)OC)OC
BQR-695(cas 1513879-21-4) is a PI4KIIIβ inhibitor with IC50s of 80 and 3.5 nM for human PI4KIIIβ and Plasmodium variant of PI4KIIIβ, respectively.
1. Protein Sci. 2016 Apr;25(4):826-39. doi: 10.1002/pro.2879. Epub 2016 Feb 1.
Using hydrogen deuterium exchange mass spectrometry to engineer optimized constructs for crystallization of protein complexes: Case study of PI4KIIIβ with Rab11.
Fowler ML(1), McPhail JA(1), Jenkins ML(1), Masson GR(2), Rutaganira FU(3), Shokat KM(3), Williams RL(2), Burke JE(1).
Author information:
(1)Department of Biochemistry and Microbiology, University of Victoria, British Columbia, V8P 5C2, Canada. (2)MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0QH, United Kingdom. (3)Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California, San Francisco (UCSF), California, 94158.
The ability of proteins to bind and interact with protein partners plays fundamental roles in many cellular contexts. X-ray crystallography has been a powerful approach to understand protein-protein interactions; however, a challenge in the crystallization of proteins and their complexes is the presence of intrinsically disordered regions. In this article, we describe an application of hydrogen deuterium exchange mass spectrometry (HDX-MS) to identify dynamic regions within type III phosphatidylinositol 4 kinase beta (PI4KIIIβ) in complex with the GTPase Rab11. This information was then used to design deletions that allowed for the production of diffraction quality crystals. Importantly, we also used HDX-MS to verify that the new construct was properly folded, consistent with it being catalytically and functionally active. Structures of PI4KIIIβ in an Apo state and bound to the potent inhibitor BQR695 in complex with both GTPγS and GDP loaded Rab11 were determined. This hybrid HDX-MS/crystallographic strategy revealed novel aspects of the PI4KIIIβ-Rab11 complex, as well as the molecular mechanism of potency of a PI4K specific inhibitor (BQR695). This approach is widely applicable to protein-protein complexes, and is an excellent strategy to optimize constructs for high-resolution structural approaches.
Related Products
  • CAS No. :1245319-54-3
    Product Name:

    PI4KIII beta inhibitor 3

    Cat No: I000971 View details